Wolfgang Miesbach: Discussing Immunological Challenges in Hemophilia at GTH 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“A standout session at GTH was ‘The immunogenicity of therapeutic proteins in hemostasis – an overview’ by Sebastien Lacroix-Desmazes.
The talk clearly highlighted the immunological challenges in haemophilia — from classical FVIII inhibitors to gene therapy and anti-drug antibodies (ADAs) against newer engineered therapies.
One especially interesting point: FVIII-mimetic bispecific antibodies do not seem to share the same immunogenic profile
- Emicizumab։ ADA signal reported
- NXT007։ ADA signal also observed in early studies
- Mim8։ no ADA signal in the study presented
A likely reason is molecular design:
- Emicizumab is a humanized and highly engineered bispecific antibody; such optimization can improve function, but may also introduce non-self sequences or neoepitopes.
- NXT007, as a further optimized derivative, may retain or add immunogenic determinants.
- Mim8, with a more fully human design strategy, may reduce immune recognition
Take-home message:
Shared mechanism does not equal shared immunogenicity. Even when therapies target the same pathway, immune responses can differ because of humanization strategy, sequence design, and epitope architecture.”
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show